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Abstract
Objectives—To assess the influence of parity, as a proxy for exposure to children, and sexual 
history on cytomegalovirus (CMV) seroprevalence among women in the United States.
Methods—We analyzed data of 3710 women 20-49 years-old who were tested for CMV IgG 
antibodies in the 1999-2004 National Health and Nutrition Examination Survey, a nationally 
representative, cross-sectional survey of the non-institutionalized U.S. population. We performed 
logistic regression to determine independent variables associated with CMV seroprevalence.
Results—In age-adjusted univariate analysis, women who had given birth to ≥1 child had a 
higher overall CMV seroprevalence (66.0%; 95% confidence interval [CI]: 63.1-68.9%) compared 
to those who had not (49.0%; 95% CI: 44.4-53.7%) (p<0.001). Higher CMV seroprevalence was 
independently associated with increasing number of live births (adjusted Odds Ratio [aOR]=1.2, 
95%CI=1.1-1.3, for each additional live birth), age at first sexual intercourse <18 vs. ≥18 years 
(aOR=1.3, 95%CI=1.1-1.6), number of life time sexual partners ≥10 vs. <10 (aOR=1.4, 
95%CI=1.1-1.9), and herpes type II positivity (aOR=1.9, 95%CI=1.5-2.6) after controlling for age 
group, race/Hispanic origin, place of birth, poverty index ratio, and education level (p<0.05).
Conclusions—In this population-based sample of U.S. women of reproductive age, parity and 
sexual exposures were independently associated with higher CMV seroprevalence.
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INTRODUCTION
An estimated 0.7% or 28,000 children are born with congenital cytomegalovirus (CMV) 
infection annually in the United States [1]. Mother-to-fetus transmission, congenital CMV 
disease at birth and permanent disabilities due to congenital CMV infection are more likely 
when CMV infection during pregnancy occurs in CMV seronegative women, but can result 
from non-primary infections (reinfection or reactivation) in CMV seropositive women [2]. In 
the United States, the overall CMV IgG seroprevalence among women 12-49 years-old is 
57.9% [3]. The estimated annual seroconversion rate among the general population of 
pregnant women is 2.3%, but is approximately 10 times higher among parents with a child 
shedding CMV [4].
Previous studies have shown that women caring for young children and with recent onset of 
sexual activity are at greatest risk of having an infant with congenital CMV infection, with 
adolescent mothers likely disproportionally affected by the disease burden caused by 
congenital CMV infection [5, 6]. However, the highest birth rates among U.S. women are 
observed in their 20s and early 30s. The extent to which these women remain susceptible to 
primary CMV infections throughout successive pregnancies is not well understood. We 
assessed the influence of parity, as a proxy for exposure to children, and sexual history on 
CMV seroprevalence among women 20-49 years-old in the United States.
METHODS
The National Health and Nutrition Examination Survey (NHANES) is a nationally 
representative, cross-sectional survey of the non-institutionalized U.S. population conducted 
by the Centers for Disease Control and Prevention since the 1970s. Data collection consists 
of: 1) a household screener to determine eligibility of any household members for the 
interview or examination; 2) an interview of eligible sample person to collect person-level 
data on demographics, health, and nutrition, and household information; and 3) a physical 
examination which includes collection of specimens for laboratory testing. Detailed methods 
of the NHANES have been published elsewhere [7]. The National Center for Health 
Statistics Research Ethics Review Board, Centers for Disease Control and Prevention, 
reviewed and approved all protocols for the conduct of NHANES 1999-2004. All 
participants provided written informed consent, including consent to have their blood, urine, 
and saliva specimens stored for future studies [7]. CMV-specific IgG antibody testing was 
performed in stored sera from NHANES 1999-2004, using ELISA (Quest International, Inc., 
Miami FL) [8], and results were added to the NHANES database which is publicly available.
A previous analysis of the 1999-2004 NHANES has shown that CMV seroprevalence was 
independently associated with older age, female sex, low household income, high household 
crowding, low education, and foreign country of birth [9]. We focused our analysis on 
women age 20-49 years because complete risk factor data were not available for women age 
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<20 years. We calculated seroprevalence for CMV IgG among women, overall and by age 
group (20-29, 30-39, 40-49 years), race/Hispanic origin, country of birth, household income 
and index ratio of family income to poverty, insurance status, education level, household 
crowding, age when had first live birth, parity (number of live births), and sexual history 
variables. Race/Hispanic origin was based on the respondents’ self-assessment and 
categorized as non-Hispanic White, non-Hispanic Black, Mexican American, or other, which 
included non-Hispanic Asians, other Hispanics, and multi-racial. Country of birth was 
categorized as U.S. or non-U.S. The family income to poverty ratio, calculated by dividing 
family income by a poverty threshold specific for family size using the U.S. Department of 
Health and Human Services’ 2012 poverty guidelines, was categorized as below (<1.0) or at 
or above the poverty threshold (≥1.0) [10]. Household crowding index was calculated 
dividing the household size by the number of rooms in the household, excluding bathrooms, 
and categorized as low (<0.5 persons per room), average (0.5-0.99 persons per room), or 
high (≥1 persons per room). Sexual history variables included age at first intercourse, 
number of lifetime sexual partners, herpes type II seropositivity, self-report of ever being 
diagnosed with any of four sexually transmitted diseases (chlamydia, gonorrhea, genital 
herpes, or genital warts), and any oral contraceptive use.
We calculated national estimates of CMV seroprevalence using the weights developed for 
the NHANES to represent the total civilian non-institutionalized U.S. household population 
and to account for oversampling and nonresponse to the household interview and physical 
examination [11]. There were 5291 women age 20-49 sampled in NHANES 1999-2004, of 
whom 4264 (80.6% of those sampled) were interviewed and 4042 (94.8% of those 
interviewed) were examined. Among those examined 3710 (91.8%) were tested for CMV 
IgG. Because the percent of those tested among those examined varied by <5% across levels 
of each variable analyzed we used the original NHANES exam weights without adjustment 
for non-response.
We estimated standard errors using Taylor Series Linearization, a design-based method 
which incorporates sample weights and accounts for stratification and clustering of the 
NHANES sample design [11]. We considered estimates unstable if: 1) the relative standard 
error (defined as the estimate divided by its standard error expressed as a percent) around the 
proportion of participants who were seropositive or seronegative was >30%; or 2) the 
estimate was based on <10 seropositive or seronegative persons. We used the exact binomial 
method to calculate 95% CIs. We evaluated pairwise differences between seroprevalence 
estimates and trends using a t-statistic from an orthogonal linear contrast procedure. We 
considered p-values <0.05 significant, with no adjustments for multiple comparisons.
We performed univariate analysis of CMV seroprevalence by sociodemographic variables, 
parity and sexual history variables. Because the age distribution varied by many of these 
variables and age was strongly associated with CMV seroprevalence, we standardized the 
estimates to the 2000 U.S. population age structure using the direct method to remove the 
confounding effect of age. We performed logistic regression to calculate adjusted odds ratios 
and 95% CI and determine independent variables associated with CMV seroprevalence. We 
included in the initial model all variables that were significant in the univariate analysis. 
Using backward stepwise elimination, we subsequently excluded variables no longer 
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significantly associated with CMV seroprevalence. Variables that remained in the final 
model were those with p-values <0.05 based on the Satterthwaite-adjusted F-statistic. We 
used SUDAAN Version 9.0 (Research Triangle Institute, Research Triangle Park, NC) for all 
analysis.
RESULTS
Overall CMV seroprevalence among women 20-49 years-old was 61.3% (95% CI: 
58.9-63.6%) (Table 1). In univariate analysis, CMV seroprevalence was higher among 
women who were 30-39 and 40-49 years-old compared to 20-29 years-old. In age-
standardized univariate analyses, CMV seroprevalence was higher among non-Hispanic 
Blacks and Mexican Americans than non-Hispanic Whites as well as higher among women 
born outside of the US, living below poverty, with less education, no health insurance, and 
high household crowding (p<0.001) (Table 1).
Overall age-standardized CMV seroprevalence was higher among women who had given 
birth to ≥1 child compared to women who had not, 66% vs. 49%, respectively (p<0.001) 
(Table 2). Similarly, CMV seroprevalence was significantly higher among women who had 
given birth to ≥1 child compared to women who had not given birth across all age and race/
Hispanic origin groups (Table 2).
The multivariate logistic model included 2643 women with complete risk factor data. Higher 
CMV seroprevalence was independently associated with increasing number of live births, 
younger age at first sexual intercourse, ≥10 life time sexual partners and herpes type II-
seropositivity, after controlling for age group, race/Hispanic origin, country of birth, living 
below poverty, and education level (Table 1). Considering number of live births as a 
continuous variable in the same multivariate logistic model, the adjusted odds ratio for each 
additional live birth was 1.2 (95%CI=1.1-1.3), with a significant trend (p-value<0.001).
DISCUSSION
In this population-based sample of U.S. women, increasing number of live births, early 
sexual debut, ≥10 life time sexual partners, and herpes type II seropositivity, were 
independently associated with higher CMV seroprevalence, after controlling for age and 
other sociodemographic risk factors. A previous study using data from the 1988-1994 
NHANES found that sexual exposures were associated with higher CMV seroprevalence but 
did not assess the influence of parity [12]. Two studies among pregnant women found that 
increasing parity was independently associated with higher CMV seroprevalence, after 
controlling for age and sociodemographic risk factors, but sexual exposures were not 
included [13, 14]. We found that higher CMV seroprevalence was associated with having at 
least one live birth, overall and across all age and race/Hispanic groups. Approximately half 
of women who had not given birth remain susceptible to primary CMV infection, decreasing 
to approximately one third for women with ≥1 live birth.
Parents with a child shedding CMV and child care workers have annual CMV 
seroconversion rates that are much higher (3 to 12-fold) than those of parents with a child 
not shedding CMV [4]. CMV infection early in life can result from mother-to-infant 
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transmission through exposure to CMV in genital secretions during labor or in breastmilk or 
saliva. Additionally, close contact among children in the household or day care settings can 
result in horizontal transmission from child to child. Since young CMV-seropositive children 
may shed virus in body fluids for months after primary infection [15], the risk-period for 
CMV transmission from child to mother could coincide with a subsequent pregnancy. The 
risk of CMV seroconversion among women has been shown to increase over time 
throughout successive pregnancies [16]. The highest risk of congenital CMV infection in a 
study of infants born to mothers who seroconverted between deliveries was associated with 
an interval of <24 months between deliveries [17]. Data on interval between pregnancies and 
birth order for newborns with congenital CMV infection identified through population-based 
screening studies might be helpful to identify groups at highest risk.
Congenital CMV infection is also an important concern for women who are already 
seropositive when they become pregnant [17]. A study in the U.S. found a 10% annualized 
rate of reinfection among CMV seropositive women [18]. In populations with high maternal 
CMV seroprevalence, reinfection with a new CMV strain was a risk factor for delivering an 
infant with congenital CMV infection. In a study in Brazil, the annualized rate of reinfection 
among women delivering an infant with congenital CMV infection was 35% compared to 
9% among women delivering uninfected infants [19]. Although the rate of mother-to-fetus 
transmission from non-primary infections is lower than with primary infection [2], non-
primary maternal infections are estimated to account for the majority of congenital CMV 
infections [20-22] and CMV-related hearing loss [22]. Risk factors for CMV reinfection and 
reactivation are not well understood.
Our study had some limitations. Because NHANES is a cross-sectional study, we could not 
determine when seroconversion occurred. We used parity as a proxy to exposure to young 
children but data on general or occupational exposures to children were not available. We 
did not include women <20 years of age in the analysis because we did not have complete 
data on sexual exposures.
Routine serologic screening for CMV infection during pregnancy is not currently 
recommended in the United States [23]. Maternal IgM screening has limitations in 
differentiating primary from non-primary infections and IgG avidity tests are not widely 
available commercially [3, 23]. In addition, pre-conceptional immunity does not completely 
eliminate the risk of congenital CMV infection, effective treatments to prevent fetal infection 
are lacking, and the data on effectiveness of hygiene interventions targeted at pregnant 
women to reduce the risk of congenital CMV infection are limited [23]. We observed higher 
susceptibility to primary CMV infection among women <30 years who had not given birth. 
CMV seroprevalence remained fairly constant between 1988-1994 and 1999-2004 [9], 
whereas fertility rates among U.S. women <25 years-old has shown a substantial decline 
over the last decades [24]. A better understanding of the impact of declining fertility rates 
among younger women on the prevalence of congenital CMV infection is needed. The data 
we present can be modeled to assess secular trends in the prevalence of congenital CMV 
infection and produce more robust estimates of congenital CMV infection resulting from 
primary and non-primary maternal infection. This, in turn, would be useful for assessing the 
impact of interventions that might be implemented in the future.
Lanzieri et al. Page 5














[1]. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory 
sequelae and mortality associated with congenital cytomegalovirus infection. Reviews in medical 
virology. 2007; 17(5):355–363. [PubMed: 17542052] 
[2]. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus 
infection. JAMA. 2003; 289(8):1008–1011. [PubMed: 12597753] 
[3]. Dollard SC, Staras SA, Amin MM, Schmid DS, Cannon MJ. National prevalence estimates for 
cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low 
IgG avidity. Clinical and vaccine immunology. 2011; 18(11):1895–1899. [PubMed: 21918114] 
[4]. Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk factors: 
implications for congenital CMV. Reviews in medical virology. 2010; 20(5):311–326. [PubMed: 
20645278] 
[5]. Fowler KB, Pass RF. Risk factors for congenital cytomegalovirus infection in the offspring of 
young women: exposure to young children and recent onset of sexual activity. Pediatrics. 2006; 
118(2):e286–292. [PubMed: 16847076] 
[6]. Fowler KB, Stagno S, Pass RF. Maternal age and congenital cytomegalovirus infection: screening 
of two diverse newborn populations, 1980-1990. The Journal of infectious diseases. 1993; 
168(3):552–556. [PubMed: 8394857] 
[7]. Zipf G, Chiappa M, Porter KS, Harris C, Ostchega W, Lewis BG, et al. National Health and 
Nutrition Examination Survey: Plan and operations, 1999-2010. National Center for Health 
Statistics Vital Health Statistics. 2013; 1(56) [Accessed December 17, 2015]
[8]. Centers for Disease Control and Prevention. National Center for Health Statistics. Division of 
Health and Nutrition Examination Surveys. [Accessed December 17, 2015] National Health and 
Nutrition Examination Survey, 2003-2004: Data Documentation, Codebook, and Frequencies. 
2008. 
[9]. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the 
national health and nutrition examination surveys, 1988-2004. Clinical infectious diseases. 2010; 
50(11):1439–1447. [PubMed: 20426575] 
[10]. U.S. Department of Health and Human Services. [Accessed December 17, 2015] Poverty 
Guidelines, Research, and Measurement. 2012. 
[11]. Centers for Disease Control and Prevention. National Center for Health Statistics. Division of 
Health and Nutrition Examination Surveys. [Accessed December 17, 2015] National Health and 
Nutrition Examination Survey: Analytic Guidelines, 2011-2012. 2013. 
[12]. Staras SA, Flanders WD, Dollard SC, Pass RF, McGowan JE Jr. Cannon MJ. Influence of sexual 
activity on cytomegalovirus seroprevalence in the United States, 1988-1994. Sexually transmitted 
diseases. 2008; 35(5):472–479. [PubMed: 18354346] 
[13]. Tookey PA, Ades AE, Peckham CS. Cytomegalovirus prevalence in pregnant women: the 
influence of parity. Arch Dis Child. 1992; 67(7 Spec No):779–783. [PubMed: 1325757] 
[14]. Gratacap-Cavallier B, Bosson JL, Morand P, Dutertre N, Chanzy B, Jouk PS, et al. 
Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major 
predictive factors. European journal of epidemiology. 1998; 14(2):147–152. [PubMed: 9556173] 
[15]. Cannon MJ, Hyde TB, Schmid DS. Review of cytomegalovirus shedding in bodily fluids and 
relevance to congenital cytomegalovirus infection. Reviews in medical virology. 2011; 21(4):
240–255. [PubMed: 21674676] 
[16]. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, et al. Primary cytomegalovirus 
infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA. 1986; 
256(14):1904–1908. [PubMed: 3020264] 
[17]. Fowler KB, Stagno S, Pass RF. Interval between births and risk of congenital cytomegalovirus 
infection. Clinical infectious diseases. 2004; 38(7):1035–1037. [PubMed: 15034839] 
[18]. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, Boppana SB. Cytomegalovirus reinfections in 
healthy seroimmune women. The Journal of infectious diseases. 2010; 201(3):386–389. 
[PubMed: 20039807] 
Lanzieri et al. Page 6













[19]. Yamamoto AY, Mussi-Pinhata MM, Boppana SB, Novak Z, Wagatsuma VM, Oliveira Pde F, et 
al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly 
cytomegalovirus-immune maternal population. American journal of obstetrics and gynecology. 
2010; 202(3):297, e291–298. [PubMed: 20060091] 
[20]. Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to 
primary versus non-primary maternal infection. Clinical infectious diseases. 2011; 52(2):e11–13. 
[PubMed: 21288834] 
[21]. Lanzieri TM, Bialek SR, Ortega-Sanchez IR, Gambhir M. Modeling the potential impact of 
vaccination on the epidemiology of congenital cytomegalovirus infection. Vaccine. 2014; 32(30):
3780–3786. [PubMed: 24837782] 
[22]. de Vries JJ, van Zwet EW, Dekker FW, Kroes AC, Verkerk PH, Vossen AC. The apparent 
paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a 
population-based prediction model. Reviews in medical virology. 2013; 23(4):241–249. 
[PubMed: 23559569] 
[23]. American College of Obstetricians and Gynecologists. Cytomegalovirus, parvovirus B19, 
varicella zoster, and toxoplasmosis in pregnancy. Practice Bulletin No. 151. Obstet Gynecol. 
2015; 125:1510–1525. [PubMed: 26000539] 
[24]. Martin JA, Hamilton BE, Osterman MJ. Births in the United States, 2014. NCHS Data Brief. 
2015; (216):1–8. [PubMed: 26460599] 
Lanzieri et al. Page 7














Parity and sexual exposures are independently associated with higher CMV 
seroprevalence among U.S. women of reproductive age, after controlling for age and 
sociodemographic risk factors.
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Table 1
Age-adjusted CMV seroprevalence among women 20-49 years-old by sociodemographics, parity and sexual 
history, NHANES 1999-2004
Characteristic












Examined Tested forCMV IgG
Overall 4042 3710 (91.8) 61.3 (58.9-63.6)
Age group (years)
20-29 1502 1357 (90.3) 52.5 (48.9-56.1) Ref
30-39 1343 1242 (92.6) 64.2 (60.3-67.9)b 1.9 (1.5-2.5) <0.001
40-49 1197 1111 (92.8) 66.0 (61.8-69.9)b 1.9 (1.3-2.8) <0.001
Race/Hispanic origin
Non-Hispanic White 1791 1654 (92.4) 48.6 (45.9-51.3) Ref
Non-Hispanic Black 861 776 (90.1) 87.1 (84.2-89.6)b 4.8 (3.5-6.7) <0.001
Mexican American 1006 932 (92.6) 87.6 (84.2-90.5)b 4.4 (3.0-6.5) <0.001
Other 384 348 (90.6) 83.1 (76.5-88.4)
Country of birth
U.S. 3031 2790 (92.1) 55.8 (53.2-58.4) Ref
Non-U.S. 1011 920 (91.0) 90.2 (86.4-93.3)b 2.9 (1.6-5.3) <0.001
Family income to poverty ratio
Below poverty threshold 866 795 (91.9) 78.7 (74.1-82.8)b 1.7 (1.1-2.5) 0.010
At or above poverty threshold 2857 2648 (92.7) 57.0 (54.2-59.7) Ref
Education level
Below high school 1037 935 (90.2) 84.6 (80.9-87.8)b 2.2 (1.5-3.4) <0.001
High school 935 854 (91.3) 66.0 (61.5-70.3)b 1.6 (1.2-2.1) <0.003
Above high school 2066 1917 (92.8) 52.9 (49.6-56.1) Ref
Household crowding index
High 965 903 (93.6) 85.6 (82.1-88.7)b - 0.074c
Average 1963 1800 (91.7) 61.2 (58.5-63.9)b - 0.356c
Low 1067 974 (91.3) 50.0 (45.9-54.1) Ref
Health insurance status
Any insurance 3031 2786 (91.9) 57.6 (55.1-60.0) - 0.151c
No insurance 963 889 (92.4) 75.3 (70.6-79.7)b Ref
Number of live births
0 775 715 (92.3) 49.0 (44.4-53.7) Ref
1 761 709 (93.2) 60.1 (54.6-65.3) 1.3 (1.0-1.8) 0.101
2 905 860 (95.0) 64.8 (60.8-68.6) 1.6 (1.1-2.3) 0.011
3 604 567 (93.9) 74.5 (69.1-79.3) 1.9 (1.3-2.8) 0.003
4 228 215 (94.3) 78.2 (64.0-88.7) 2.0 (1.1-3.6) 0.026
≥5 161 153 (95.0) 83.8 (62.5-95.7)d 2.5 (0.8-7.5)e 0.100
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Characteristic












Examined Tested forCMV IgG
Age at first sexual intercourse
<18 years 1963 1838 (93.6) 64.4 (61.4-67.3)b 1.3 (1.1-1.6) 0.017
≥18 years 1568 1459 (93.1) 55.7 (52.2-59.1) Ref
Number of life time sexual
partners
0-9 2764 2579 (93.3) 58.2 (55.5-60.9) Ref
≥10 742 696 (93.8) 66.3 (62.3-70.2)b 1.4 (1.1-1.9) 0.012
Herpes type II serology
Positive 1057 1049 (99.2) 76.6 (73.7-79.3) b 1.9 (1.5-2.6) <0.001
Negative 2658 2608 (98.2) 55.2 (52.3-58.1) Ref
History of sexually transmitted
disease
Any 388 365 (94.1) 67.8 (61.0-74.1)f - 0.527c
None 3144 2935 (93.4) 59.5 (56.9-62.1) Ref
Oral contraceptive use
Any 2693 2532 (94.1) 59.2 (56.4-61.9)f - 0.852c
None 902 823 (91.2) 66.7 (61.2-71.8) Ref
a
Adjusted odds ratios obtained from the final logistic regression model (n=2643) that included age group, race/Hispanic origin, country of birth, 
family income to poverty ratio, education level, number of live births, age of first sexual intercourse, number of life time sexual partners and herpes 
type II serology. Group representing ‘other’ race/Hispanic origin not included in the logistic regression model.
b
P-value <0.001 from univariate analysis comparing subgroup to reference group for each cofactor
c
P-values for beta based on the full logistic regression model.
d
Estimate considered unstable because relative standard error of percent negative was >30%
e
P-value <0.001 for test of linear trend with increasing number of live births from 0-5 or more
f
P-value <0.05 from univariate analysis comparing subgroup to reference group for each cofactor
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Table 2
CMV seroprevalence among women 20-49 years-old by parity and age group or age-adjusted by race/Hispanic 
origin, NHANES 1999-2004
Characteristic
n, CMV Seroprevalence, % (95% CI)
P-
valueaWomen who had given
birth to ≥1 child
Women who had not
given birth
Overall 2503 66.0 (63.1-68.9) 715 49.0 (44.4-53.7) <0.001
Age group
20-29 685 62.5 (57.1-67.7) 426 40.7 (35.4-46.1) <0.001
30-39 915 68.2 (63.5-72.7) 168 52.8 (43.5-62.0) 0.004
40-49 903 66.9 (62.2-71.3) 121 52.6 (42.7-62.3) 0.007
Race/Hispanic origin
Non-Hispanic White 1058 52.6 (48.7-56.4) 386 39.2 (33.2-45.4) <0.001
Non-Hispanic Black 544 90.1 (87.2-92.5) 123 74.5 (63.9-83.3) 0.002
Mexican American 691 91.2 (88.2-93.6) 120 71.4 (58.4-82.2) 0.001
a
P-value from t-test comparing women who have given birth at least once to those who have never given birth
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